← Leaderboards
Brian Matthew Zeglis
Sloan-Kettering Inst Can Research
$6,881,872
Attributed
$13,897,251
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,897,251 · 10
By mechanism
R01$8,527,790 · 4
U01$3,484,029 · 1
R21$886,607 · 2
R00$746,997 · 1
F32$144,150 · 1
K99$107,678 · 1
Top collaborators
- Jason S Lewis10 shared
- Weigang Qiu5 shared
- Gary Allan Ulaner5 shared
- Brian Agnew4 shared
- Delphine L Chen3 shared
- Maria Gomes-Solecki3 shared
- Paul D Lampe3 shared
- John L Humm1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Thomas Reiner$4,804,085
- John Thomas Poirier$4,490,380
- Wolfgang Weber$588,124
- Jan-Philip Meyer$67,966
- Nagavarakishore Pillarsetty$8,324,037
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoImagePositron-Emission TomographyLabelSiteBiodistributionBaseDesignMouse ModelRadioimmunoconjugateUptakeLeadPerformanceAntibodiesImmunoconjugatesTumorRadiolabeledLaboratoriesRadiopharmaceuticalsTissuesIn VitroReactionClinicRadioisotopes
Grant awards (31)
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer$645,551
R01 · FY2025 · CA
ImmunoPET Probes for the Imaging of Lyme Disease$552,686
R01 · FY2025 · AI · contact PI
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer$613,760
R01 · FY2024 · CA
ImmunoPET Probes for the Imaging of Lyme Disease$556,751
R01 · FY2024 · AI · contact PI
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer$582,047
R01 · FY2023 · CA
ImmunoPET Probes for the Imaging of Lyme Disease$565,163
R01 · FY2023 · AI · contact PI
Targeting DNA Mismatches for Auger Electron Radiotherapy$457,607
R21 · FY2023 · CA · contact PI
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations$323,715
R01 · FY2023 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$688,387
U01 · FY2022 · CA
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations$329,317
R01 · FY2022 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$689,177
U01 · FY2021 · CA
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations$341,585
R01 · FY2021 · CA · contact PI
A PET Radiotracer for Diagnostic and Theranostics Imaging in Lyme Disease$234,000
R21 · FY2021 · EB · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$702,430
U01 · FY2020 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$684,004
R01 · FY2020 · CA
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations$310,529
R01 · FY2020 · CA · contact PI
A PET Radiotracer for Diagnostic and Theranostics Imaging in Lyme Disease$195,000
R21 · FY2020 · EB · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$706,245
U01 · FY2019 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$679,482
R01 · FY2019 · CA
Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations$315,900
R01 · FY2019 · CA · contact PI
Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer$697,790
U01 · FY2018 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$674,466
R01 · FY2018 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$667,617
R01 · FY2017 · CA
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry$248,999
R00 · FY2017 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$685,217
R01 · FY2016 · CA
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry$248,999
R00 · FY2016 · CA · contact PI
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry$248,999
R00 · FY2015 · CA · contact PI
Pretargeted Radioimmunotherapy Based on Bioorthogonal Click Chemistry$107,678
K99 · FY2014 · CA · contact PI
PET Imaging of Topoisomerase-II Expression in Breast Cancer$51,326
F32 · FY2011 · CA · contact PI
PET Imaging of Topoisomerase-II Expression in Breast Cancer$47,606
F32 · FY2010 · CA · contact PI
PET Imaging of Topoisomerase-II Expression in Breast Cancer$45,218
F32 · FY2009 · CA · contact PI